Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Immunomedics, Inc. (IMMU), ImmunoGen, Inc. (IMGN): Should You Invest in These Cancer Treatment Biotechs?

Therefore, it wasn’t surprising that Onyx recently became a major acquisition target for several larger pharmaceutical companies. Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) put itself up for sale on June 30, citing “expressions of interest” from potential suitors, and stated that it had already rejected an $8.7 billion offer from Amgen, Inc. (NASDAQ:AMGN), which valued the company at $120 per share. As a result, Onyx shares surged over 50% on July 1 to close at $131.

Amgen, Inc. (NASDAQ:AMGN) could increase its bid in the near future, since it desperately needs to strengthen its drug development pipeline. Over the past three years, the FDA has raised safety concerns regarding Amgen’s anemia drugs, and the patents on four of its five best-selling drugs will expire starting in 2015. In addition, Onyx’s announcement has also reportedly attracted the attention of Pfizer Inc. (NYSE:PFE) and Novartis AG (ADR) (NYSE:NVS), which could start a bidding war to acquire Onyx’s cancer drugs portfolio. With $21 billion in cash, Amgen certainly has the resources to acquire Onyx, but it would be the company’s second largest acquisition ever, after its $16 billion acquisition of Immunex in 2002.

The Foolish Bottom Line

Biotechs such as Immunomedics, ImmunoGen, Inc. (NASDAQ:IMGN), Seattle Genetics and Onyx Pharmaceuticals are exciting to invest in, but investors should be aware that market movements in this sector are more driven by clinical trials, approvals, and buyouts than fundamentals. For ADCs, I believe that Seattle Genetics is the safest bet, thanks to its size and heavy industry partnerships, and it could take off over the next few years as more of its ADCs are approved. For cancer drugs, I think that Onyx’s attractive revenue stream (up 102% year-on-year last quarter) will attract more buyers, and that investors could still see a significant boost from its current price.

However, I encourage investors to do their due diligence with these stocks, since investing in biotechs with only a cursory understanding of their drug pipelines can be highly toxic for your portfolio.

Leo Sun has no position in any stocks mentioned. The Motley Fool recommends ImmunoGen and Seattle Genetics.

The article Should You Invest in These Cancer Treatment Biotechs? originally appeared on Fool.com and is written by Leo Sun.

Leo is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.